NETRIS Pharma

What NETRIS Pharma does

NETRIS Pharma is a privately held, clinical-stage biopharmaceutical company headquartered in Lyon, France (28 rue Laennec, within Centre Léon Bérard), spun out in 2008 from Centre Léon Bérard and the Cancer Research Center of Lyon (CRCL). The company is developing first-in-class therapeutics that block netrin-1 — a developmental secreted protein re-expressed by tumors as a survival mechanism — to restore dependence-receptor-mediated cell death and inhibit epithelial-to-mesenchymal transition (EMT), a central mechanism of acquired resistance to chemotherapy, targeted therapy, and immunotherapy.

The lead asset NP137 is a humanized IgG1 monoclonal antibody currently evaluated across five Phase 1b and Phase 2 clinical trials in solid tumors, including locally advanced pancreatic ductal adenocarcinoma (LAPNET-01, published in Nature 2026), head and neck squamous cell carcinoma (ImmunoNET and an upcoming Phase 2b funded by Horizon Europe), hepatocellular carcinoma (Liver-NET1 with atezolizumab/bevacizumab), endometrial and cervical cancer (GyNET with Merck/MSD-supplied pembrolizumab), and NSCLC/melanoma. Clinical results to date show a 10.85-month median PFS and 23% conversion-to-surgery rate in LAPC, improving to 15.65 months PFS and 40% conversion in neogenin-high patients — supporting the company's planned neogenin IHC companion diagnostic. The pipeline extends to NP137P (endometriosis, €3.9M BPI France grant), NP137R (anti-netrin-1 radioligand therapy with INSERM and Orano), and NP800 (glioblastoma).

Commercially, NETRIS is pre-revenue; its model is to advance NP137 through clinical trials sponsored by academic cancer centers and cooperative oncology groups (GORTEC, TTCC, Centre Léon Bérard) toward regulatory approval in the US and EU, then distribute through standard hospital/specialty pharmacy channels. The company is governed by a full C-suite (CEO/CSO/CMO/CFO/CBO) and an independent board (Jean-Pierre Bizzari, Gabriela Gruia, Luc Otten), and has raised approximately €24.4M in Series A funding (extended Dec 2023 with the EIC Fund), supplemented by €7.25M Horizon Europe, €1.2M Eurostar, and €3.9M BPI France grants.

Name

NETRIS Pharma

Legal name

NETRIS PHARMA

Website

https://netrispharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

NETRIS Pharma is a clinical-stage biopharmaceutical company developing NP137, a first-in-class monoclonal antibody blocking netrin-1 to overcome cancer treatment resistance, with an active multi-indication Phase 1b/2 oncology pipeline and a Lyon, France base as a spin-off of Centre Léon Bérard.

Ownership category

akta.pro rank

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue (Post-Approval): NETRIS Pharma is a clinical-stage biopharmaceutical company with no current revenue. The company is developing NP137, a monoclonal antibody, through clinical trials toward regulatory approval and commercialization. Revenue would be generated from product sales upon approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

NETRIS Pharma develops first-in-class anti-netrin-1 monoclonal antibody therapeutics, with lead asset NP137 (humanized IgG1 mAb) currently in multiple Phase 1b/2 clinical trials across solid tumor indications (pancreatic, hepatocellular, head and neck, endometrial, cervical, NSCLC, melanoma) to overcome EMT-mediated resistance to chemotherapy and immunotherapy. The pipeline also includes NP137P for endometriosis, NP137R radioligand therapy, and NP800 for glioblastoma. The company plans to commercialize NP137 via hospital and specialty pharmacy channels upon regulatory approval, supported by a planned neogenin IHC companion diagnostic.

Product overview

NETRIS Pharma is a clinical-stage biopharmaceutical company developing a portfolio of first-in-class therapeutics targeting the netrin-1/dependence receptor axis to overcome cancer treatment resistance. The lead product NP137 is a humanized monoclonal antibody currently in multiple Phase 1/2 clinical trials across solid tumor indications including pancreatic cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, endometrial cancer, and cervical cancer. The pipeline includes NP137P for endometriosis, NP137R for radioligand therapy, and NP800 for glioblastoma. The company's approach focuses on blocking epithelial-to-mesenchymal transition (EMT) to prevent metastasis and enhance efficacy of chemotherapy, targeted therapy, and immunotherapy.

Differentiator

Problem solved

Functional benefit

Products and services

• NP137 First-in-class humanized IgG1 monoclonal antibody targeting netrin-1, designed to block epithelial-to-mesenchymal transition (EMT), inhibit tumor growth, and overcome resistance to chemotherapy, targeted therapy, and immunotherapy. Currently in clinical development across multiple solid tumor indications including PDAC, HNSCC, HCC, NSCLC, melanoma, endometrial and cervical cancer.
• NP137P Pipeline product based on the anti-netrin-1 monoclonal antibody NP137, formulated and developed as a non-hormonal disease-modifying treatment for endometriosis, targeting netrin-1 to address both endometriosis-associated pain and lesion burden. Supported by a €3.9M BPI France grant.
• NP137R Pipeline product representing an anti-netrin-1 RadioLigand Therapy formulation combining the NP137 antibody with selected radioisotopes for targeted radiotherapy delivery and imaging in netrin-1 expressing cancers. Developed in collaboration with INSERM and Orano.
• NP800 Next-generation pipeline compound targeting an undisclosed ligand, being developed for glioblastoma as part of NETRIS Pharma's pipeline expansion beyond the netrin-1 axis.
• Anti-netrin-1 RadioLigand Therapy Platform Proprietary radioligand therapy platform coupling anti-netrin-1 compounds (such as NP137R) with selected radioisotopes for targeted tumor imaging and therapy in netrin-1-expressing tumors. Developed in collaboration with INSERM and Orano.

Quantifiable outcome

• Median PFS of 10.85 months in LAPC patients (vs. ~9.7 months benchmark with FOLFIRINOX alone); Neogenin-high patients: median PFS 15.65 months, 40% conversion-to-surgery rate, 100% 12-month OS rate
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou)coreStrategic or Co-development Partner · 28 May 2026GORTEC, the leading French cooperative oncology group in head and neck cancer led by Professor Jean Bourhis, is partnering with NETRIS Pharma as the sponsor and lead coordinator of the Phase 2b randomized HNSCC trial funded by Horizon Europe. GORTEC brings extensive experience conducting landmark HNSCC clinical trials.
• Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)majorStrategic or Co-development Partner · 28 May 2026TTCC (Spanish group for the treatment of head and neck tumors, chaired by Dr. Ricard Mesia) is part of the Horizon Europe-funded consortium conducting the Phase 2b HNSCC trial alongside GORTEC and NETRIS Pharma.
• Université Libre de BruxellesminorStrategic or Co-development Partner · 28 May 2026Université Libre de Bruxelles is part of the Horizon Europe-funded consortium conducting the Phase 2b HNSCC trial.
• ACTaNet ConsortiumminorStrategic or Co-development Partner · 19 January 2023A consortium of European institutions and biotech firms received a €1.2 million Eurostar grant for the ACTaNet project to develop NP137 for chronic pain treatment related to arthritis and cancer, focusing on preclinical models and biomarker validation.
• INSERMcoreStrategic or Co-development PartnerINSERM (French National Institute of Health and Medical Research) is collaborating with NETRIS Pharma on the development of anti-netrin-1 radioligand therapy, coupling anti-netrin-1 compounds with radioisotopes for imaging and therapeutic purposes.
• OranocoreStrategic or Co-development PartnerOrano, a nuclear energy company, is collaborating with NETRIS Pharma on anti-netrin-1 radioligand therapy, providing expertise in radioisotope coupling for targeted radiotherapy applications.
• Merck & Co. (MSD)majorStrategic or Co-development PartnerMerck & Co. (MSD) provides pembrolizumab (Keytruda) through a clinical trial collaboration and supply agreement for the GyNET trial (NCT04652076) combining NP137 with pembrolizumab and carboplatin/paclitaxel in endometrial and cervical cancer.
• Centre Léon BérardcoreStrategic or Co-development PartnerNETRIS Pharma is the first spin-off of Centre Léon Bérard, the largest Comprehensive Cancer Research Center in France. The company is hosted at CLB in Lyon and benefits from privileged access to world-class clinical and translational research facilities. CLB is the sponsor of the GyNET clinical trial.
• Cancer Research Center of Lyon (CRCL)coreStrategic or Co-development PartnerCRCL (Cancer Research Center of Lyon) is a co-founding institution of NETRIS Pharma along with Centre Léon Bérard. The company leverages the research environment and expertise of this cancer research center.
• Lyon Biopole AURAminorStrategic or Co-development PartnerLyon Biopole AURA is listed as a partner supporting NETRIS Pharma, providing ecosystem connections in the Auvergne-Rhône-Alpes region.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Innate Pharma: French clinical-stage biopharmaceutical company developing immuno-oncology antibodies and proprietary platforms. Comparable as a French-listed clinical-stage biotech developing oncology biologics with novel mechanisms of action, though Innate focuses on NK cell engagers and TLR agonists rather than netrin-1.
• OSE Immunotherapeutics: French clinical-stage biotech developing immuno-oncology and inflammation therapeutics, including monoclonal antibodies and bispecifics. Comparable as a clinical-stage French biotech advancing novel antibody-based oncology programs through Phase 1/2 trials.
• Transgene: French clinical-stage biotech developing immunotherapy products for solid tumors, including therapeutic vaccines and oncolytic vectors. Comparable as a Lyon-based French clinical-stage oncology company with multiple Phase 1/2 programs, though Transgene uses viral vector platforms rather than mAbs.
• Molecular Partners: Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology, including immune-engaging and targeted oncology programs. Comparable as a European clinical-stage company advancing novel biologics through multiple oncology Phase 1/2 trials.
• Compugen: Israel-based clinical-stage biotech leveraging computational biology to discover novel immuno-oncology drug targets and develop therapeutic antibodies. Comparable as a clinical-stage company developing first-in-class antibodies against novel oncology targets with multi-indication strategies.
• Alligator Bioscience: Swedish clinical-stage biotech developing tumor-directed immuno-oncology antibodies, including bispecifics. Comparable as a European clinical-stage antibody developer with multiple oncology Phase 1/2 programs and pipeline expansion through novel mechanism targets.
• Erytech Pharma: French clinical-stage biotech (Lyon-based) developing tumor-metabolism-based therapies for cancer. Comparable as a Lyon-based French clinical-stage oncology company developing novel therapeutic approaches through Phase 2/3 trials with similar size and European clinical footprint.
• Macrogenics: US-based clinical-stage biotech developing novel oncology therapeutics including monoclonal antibodies and antibody-drug conjugates. Comparable as a clinical-stage biotech with multiple oncology antibody programs in Phase 1/2 development across solid tumor indications.

Broad incumbents

• Genmab: Danish-established antibody therapeutics leader with multiple approved and clinical-stage oncology antibodies (e.g., Darzalex, partnered bispecifics). Comparable as a European antibody therapeutics specialist, though Genmab is a larger, more mature, and commercially established company with broader portfolio scope.
• MorphoSys: German clinical-stage and recently commercial antibody therapeutics company developing oncology biologics including Monjuvi (tafasitamab). Comparable as a European antibody-focused oncology company, though MorphoSys is larger with a recently approved product and broader portfolio.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/netris-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NETRIS Pharma